Castration-resistant prostate cancer (CRPC) is a common form of prostate cancer in which
docetaxel-based chemotherapy is used as the first line. The present study is devoted to the …

Excess adipose tissue is a hallmark of an overweight and/or obese state as well as a
primary risk factor for breast cancer development and progression. In an overweight/obese …

Inhibiting androgen receptor (AR) signaling with androgen deprivation therapy (ADT)
represents the mainstay of therapy for advanced and metastatic prostate cancer. However …

Metabolic phenotypes of cancer cells are heterogeneous and flexible as a tumor mass is a
hurriedly evolving system capable of constant adaptation to oxygen and nutrient availability …

Taxanes, microtubule stabilizing agents, are extensively used in the treatment of non-small
cell lung cancer (NSCLC). However, their clinical effectiveness remains restricted owing to …

Breast cancer cells modulate lipid and fatty acid metabolism to sustain proliferation. The role
of adipocytes in cancer treatment efficacy remains, however, to be fully elucidated. We …

Background Docetaxel is the preferred chemotherapeutic agent for hormone‐refractory
prostate cancer (PC) patients. However, patients eventually develop docetaxel resistance …

Prostate cancer (PCa) is known to develop resistance to chemotherapy. Growth arrest‐
specific 6 (GAS6), plays a role in tumor progression by regulating growth in many cancers …

Androgen receptor signaling regulates the normal and pathological growth of the prostate. In
particular, the growth and survival of prostate cancer cells is initially dependent on androgen …

Background Immunosuppressive cytokines have the potential to promote prostate cancer
progression. Assessing their longitudinal changes may implicate mechanisms of …